Sanofi’s Praluent Closes Gap On Repatha In Europe, As GSK Gets Green Light For World’s First Malaria Vaccine
This article was originally published in The Pink Sheet Daily
Europe’s CHMP grants positive opinions for Sanofi’s Praluent and GSK’s not-for-profit malaria vaccine Mosquirix at July meeting; other products recommended include Shire’s Intuniv, Merck’s Zerbaxa, Basilea’s Cresemba and Keryx’s Fexeric.
You may also be interested in...
India's biggest drug firm, Sun Pharma, has teamed up with the Indian Council of Medical Research in a public-private partnership to create a malaria-free India. But the initiative comes as scientists worry that a powerful new drug-resistant strain of the disease could be about to emerge in the country.
IQWIG’s review is now open for consultation, with Germany's top HTA body the G-BA expected to make a final decision about the benefits of the ultra-orphan in December.
Teva’s buyout of Allergan’s generics business should end speculation about a Teva/Mylan merger. A new Sanofi/Regeneron tie-up and an AstraZeneca divestiture to Sanofi’s Genzyme unit are among the latest developments in immuno-oncology.